Brief: Oncocyte Announces Five-Year VA Contract for DetermaRx
30/08/2022 22:55
Aug 30 (Reuters) - OncoCyte Corp OCX.O :
* ONCOCYTE ANNOUNCES FIVE-YEAR VA CONTRACT FOR DETERMARX
* ONCOCYTE CORP - U.S. DEPARTMENT OF VETERANS AFFAIRS HAS
AWARDED
CO A FEDERAL SUPPLY SCHEDULE CONTRACT FOR COMPANY'S DETERMARX
TEST
Source text for Eikon: ID:nGNX84CVJP
Further company coverage: OCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insight Molecular Diagnostics
See all newsBrief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission